Biosimilar Development insights

  1. Can A Shared Biomanufacturing Facility Be The Answer To The Demand Forecasting Dilemma?

    Using a shared biomanufacturing facility, a biomanufacturer can minimize its investment while mitigating the risks of demand uncertainty and maximizing time to market.

  2. The Top Trends Influencing Automation In The Life Science Industry 2018

    Trevor Marshall of Zenith Technologies discusses the impact that multi-product manufacturing facilities, single-use technologies, continuous manufacturing and industry 4.0 will have on automation.

  3. The Transparent CDMO: Maintaining Autonomy In Your Biomanufacturing Partnership

    Complete transparency and open communication are critical for a successful partnership. What business practices should you look for to ensure your CDMO can offer this type of commitment?

  4. Is Your Sterile Injectable Ready For Changes In Raw Materials?

    Over the life of a drug, changes in raw materials are almost inevitable. But even a small modification can throw your drug out of compliance. Using case studies, the author explains how to safeguard drug integrity when raw materials change.

  5. The Benefits Of Flow Cytometry In Immuno-Oncology Research

    Flow cytometry introduces a powerful and versatile technology into studies, enabling in-depth analysis of cell signaling and behavior.

  6. Effective Processes For Virus Purification

    An informative presentation focused on the understanding the challenges in virus/VLP purification, choosing the appropriate (or right) chromatography media for the production virus particles, and developing chromatography methods for optimal binding selectivity and recovery of virus particles.

  7. Pfizer Collaborates to Accelerate Approval of Biosimilar MAbs in China

    As Pfizer began its pursuit of delivering two biosimilar monoclonal antibodies (mAbs) in China, it sought a partner that could mitigate the risks of expanding into this region while also significantly reducing the development timeline. By leveraging the expertise of an experienced partner and the benefits of single-use technology (SUT), Pfizer was able to quickly establish a global footprint while also gaining a competitive advantage in an emerging market.

  8. Collaborating To Get Biopharma In The Fast Lane

    Scaling up a bioprocess doesn’t need to be a headache – especially when there are firms out there that can lend a helping hand.

  9. Doubling Up For Speed: Using Parallel Operations In Biopharma Manufacturing

    One solution to drug development challenges is adopting a parallel operations business model. This article offers recommendations for how parallel operations can be leveraged in a biomanufacturing strategy.

  10. Pulse Check: How To Assess Your In-House Biomanufacturing Capabilities

    By checking the pulse of your organization, you can identify gaps and develop a plan for how to address them, so you can make the right decisions at the right time.